Clone:
REAL312
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC, MICS, IHC, IF
Alternative names:
ANPEP, APN, gp150, LAP1, p150, PEPN

Extended validation for CD13 Antibody, anti-human,
REAlease
®

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REAL312
REA263++
L138-
WM15++
Cells were incubated with an excess of purified unconjugated CD13 (REAL312) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.
Knockout validation
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
View details
Overlay histogram showing flow cytometric analysis of CD13 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD13-PE, clone (REAL312). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Overlay histogram showing flow cytometric analysis of CD13 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD13-PE, clone (REAL312). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD13 Antibody, anti-human,
REAlease
®

Overview

Clone REAL312 is an antibody fragment derived from the full CD13 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL312 recognizes the CD13 antigen, a type II transmembrane glycoprotein, which is also known as aminopeptidase N or gp150. CD13 is expressed on granulocytes, myeloid progenitors, endothelial cells, epithelial cells, and subset of granular lymphoid cells. It is also broadly expressed in other tissues such as kidney proximal tubules, intestine, and placenta. CD13 is an enzyme that is used as a biomarker to detect damage to the kidneys. It also serves as a receptor for one strain of human coronavirus that is an important cause of upper respiratory tract infections. Defects in CD13 appear to be a cause of various types of leukemia or lymphoma.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

ANPEP, APN, gp150, LAP1, p150, PEPN

Detailed product information

Technical specifications

CloneREAL312
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD13
Alternative names of antigenANPEP, APN, gp150, LAP1, p150, PEPN
Distribution of antigengranulocytes, myeloid cells, endothelial cells, epithelial cells, kidney, placenta
RRIDAB_2751325, AB_2783938, AB_2751332

Resources for CD13 Antibody, anti-human,
REAlease
®

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD13 Antibody, anti-human,
REAlease
®

Publications

  1. Look, A. T. et al. (1989) Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83(4): 1299-1307
  2. Yeager, C. L. et al. (1992) Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 357(6377): 420-422
  3. Favaloro, E. J. et al. (1993) CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp. Hematol. 21(13): 1695-1701

Related products for
CD13 Antibody, anti-human,
REAlease
®

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?